The blockade of immune checkpoints in cancer immunotherapy

Cited by (1,121)

Items 1,001–1,100 of 1,121

1. Merging the best of both worlds: hybrid lipid-enveloped matrix nanocomposites in drug delivery
   Koen Raemdonck, Kevin Braeckmans, Jo Demeester, Stefaan C. De Smedt · 2013 · Chemical Society Reviews
2. Immune Checkpoint Inhibitors: Making Immunotherapy a Reality for the Treatment of Lung Cancer
   Julie Renee Brahmer, Drew M. Pardoll · 2013 · Cancer Immunology Research
3. An immunostimulatory dual-functional nanocarrier that improves cancer immunochemotherapy
   Yichao Chen, Rui Xia, Yixian Huang, Wenchen Zhao, Jiang Li, Xiaolan Zhang, Pengcheng Wang, Raman Venkataramanan, Jie Fan, Wen Xie et al. · 2016 · Nature Communications
4. Are Conventional Type 1 Dendritic Cells Critical for Protective Antitumor Immunity and How?
   Jean-Charles Cancel, Karine Crozat, Marc Dalod, Raphaël Mattiuz · 2019 · Frontiers in Immunology
5. Neurologic complications of immune checkpoint inhibitors
   Alexandra M. Haugh, John C. Probasco, Douglas Buckner Johnson · 2020 · Expert Opinion on Drug Safety
6. The cGAS/STING Pathway: A Novel Target for Cancer Therapy
   Yu Gan, Xiaoying Li, Shuangze Han, Qi Liang, Xiaoqian Ma, Pengfei Rong, Wei Wang, Wei Li · 2022 · Frontiers in Immunology
7. A Recombinant Modified Vaccinia Ankara Vaccine Encoding Epstein–Barr Virus (EBV) Target Antigens: A Phase I Trial in UK Patients with EBV-Positive Cancer
   Graham S. Taylor, Hui Jia, Kevin Joseph Harrington, Lip Wai Lee, James Turner, Kristin Ladell, David A. Price, Manjit Tanday, Jen Matthews, Claudia Roberts et al. · 2014 · Clinical Cancer Research
8. WNT signaling modulates PD-L1 expression in the stem cell compartment of triple-negative breast cancer
   Castagnoli, Lorenzo, Cancila, Valeria, Cordoba-Romero, Sandra L., Faraci, Simona, Talarico, Giovanna, Belmonte, Beatrice, Iorio, Marilena V., Milani, Matteo, Volpari, Tatiana, Chiodoni, Claudia et al. · 2019 · Oncogene
9. PD-1 expression on dendritic cells suppresses CD8⁺T cell function and antitumor immunity
   Lim, Tong Seng, Chew, Valerie, Sieow, Je Lin, Goh, Siting, Yeong, Joe Poh-Sheng, Soon, Ai Ling, Ricciardi-Castagnoli, Paola · 2016 · OncoImmunology
10. SHP2 inhibition triggers anti-tumor immunity and synergizes with PD-1 blockade
    Zhao, Mingxia, Guo, Wenjie, Wu, Yuanyuan, Yang, Chenxi, Zhong, Liang, Deng, Guoliang, Zhu, Yuyu, Liu, Wen, Gu, Yanhong, Lu, Yin et al. · 2019 · Acta Pharmaceutica Sinica B
11. Adverse Effects of Immune Checkpoint Inhibitors (Programmed Death-1 Inhibitors and Cytotoxic T-Lymphocyte-Associated Protein-4 Inhibitors): Results of a Retrospective Study
    Bajwa, Ravneet, Cheema, Anmol, Khan, Taimoor, Amirpour, Alireza, Paul, Anju, Chaughtai, Saira, Patel, Shrinil, Patel, Tejas, Bramson, Joshua, Gupta, Varsha et al. · 2019 · Journal of Clinical Medicine Research
12. Technological advances in cancer immunity: from immunogenomics to single‐cell analysis and artificial intelligence
    Xu, Ying, Su, Guan-Hua, Ma, Ding, Xiao, Yi, Shao, Zhi-Ming, Jiang, Yi-Zhou · 2021 · Signal Transduction and Targeted Therapy
13. Gasdermin D-mediated release of IL-33 from senescent hepatic stellate cells promotes obesity-associated hepatocellular carcinoma
    Yamagishi, Ryota, Kamachi, Fumitaka, Nakamura, Masaru, Yamazaki, Shota, Kamiya, Tomonori, Takasugi, Masaki, Cheng, Yi, Nonaka, Yoshiki, Yukawa-Muto, Yoshimi, Thuy, Le Thi Thanh et al. · 2022 · Science Immunology
14. Ly6Clo monocytes drive immunosuppression and confer resistance to anti-VEGFR2 cancer therapy
    Jung, Keehoon, Heishi, Takahiro, Khan, Omar F., Kowalski, Piotr S., Incio, Joao, Rahbari, Nuh N., Chung, Euiheon, Clark, Jeffrey W., Willett, Christopher G., Luster, Andrew D. et al. · 2017 · Journal of Clinical Investigation
15. Iron induces anti-tumor activity in tumor-associated macrophages
    Costa da Silva, Milene, Breckwoldt, Michael O., Vinchi, Francesca, Correia, Margareta P., Stojanovic, Ana, Thielmann, Carl Maximilian, Meister, Michael, Muley, Thomas, Warth, Arne, Platten, Michael et al. · 2017 · Frontiers in Immunology
16. Renal cell carcinoma programmed death-ligand 1, a new direct target of hypoxia-inducible factor-2 alpha, is regulated by von Hippel–Lindau gene mutation status
    Messai, Yosra, Gad, Sophie, Noman, Muhammad Zaeem, Le Teuff, Gwenael, Couve, Sophie, Janji, Bassam, Kammerer, Solenne Florence, Rioux-Leclerc, Nathalie, Hasmim, Meriem, Ferlicot, Sophie et al. · 2016 · European Urology
17. Single-Cell Genomics: A Stepping Stone for Future Immunology Discoveries
    Giladi, Amir, Amit, Ido · 2018 · Cell
18. IFN-gamma-induced PD-L1 expression in melanoma depends on p53 expression
    Thiem, Alexander, Hesbacher, Sonja, Kneitz, Hermann, di Primio, Teresa, Heppt, Markus V., Hermanns, Heike M., Goebeler, Matthias, Meierjohann, Svenja, Houben, Roland, Schrama, David · 2019 · Journal of Experimental & Clinical Cancer Research
19. Gastrointestinal and Hepatic Complications of Immune Checkpoint Inhibitors
    Cramer, Peyton, Bresalier, Robert S. · 2017 · Current Gastroenterology Reports
20. Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cells
    Knox, Tessa, Sahakian, Eva, Banik, Debarati, Hadley, Melissa, Palmer, Erica, Noonepalle, Satish, Kim, Jennifer, Powers, John, Gracia-Hernandez, Maria, Oliveira, Vasco et al. · 2019 · Scientific Reports
21. Genomic instability, inflammatory signaling and response to cancer immunotherapy
    Chen, Mengting, Linstra, Renske, van Vugt, Marcel A.T.M. · 2022 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
22. Genetics of primary sclerosing cholangitis and pathophysiological implications
    Jiang, Xiaojun, Karlsen, Tom H. · 2017 · Nature Reviews Gastroenterology & Hepatology
23. Characterization of Thyroid Disorders in Patients Receiving Immune Checkpoint Inhibition Therapy
    Lee, Hyunju, Hodi, F. Stephen, Giobbie-Hurder, Anita, Ott, Patrick A., Buchbinder, Elizabeth I., Haq, Rizwan, Tolaney, Sara, Barroso-Sousa, Romualdo, Zhang, Kevin, Donahue, Hilary et al. · 2017 · Cancer Immunology Research
24. Immune checkpoint inhibitor toxicities
    Marin-Acevedo, Julian A., Chirila, Razvan M., Dronca, Roxana S. · 2019 · Mayo Clinic Proceedings
25. Kidney-infiltrating T cells in murine lupus nephritis are metabolically and functionally exhausted
    Tilstra, Jeremy S., Avery, Lyndsay, Menk, Ashley V., Gordon, Rachael A., Smita, Shuchi, Kane, Lawrence P., Chikina, Maria, Delgoffe, Greg M., Shlomchik, Mark J. · 2018 · Journal of Clinical Investigation
26. PD-1/PD-L1 blockade enhances T-cell activity and antitumor efficacy of imatinib in gastrointestinal stromal tumors
    Seifert, Adrian M., Zeng, Shan, Zhang, Jennifer Q., Kim, Teresa S., Cohen, Noah A., Beckman, Michael J., Medina, Benjamin D., Maltbaek, Joanna H., Loo, Jennifer K., Crawley, Megan H. et al. · 2017 · Clinical Cancer Research
27. High somatic mutation and neoantigen burden are correlated with decreased progression-free survival in multiple myeloma
    Miller, A, Asmann, Y, Cattaneo, L, Braggio, E, Keats, J, Auclair, D, Lonial, S, The MMRF CoMMpass Network, Russell, S J, Stewart, A K · 2017 · Blood Cancer Journal
28. Neuropilin-1: a checkpoint target with unique implications for cancer immunology and immunotherapy
    Chuckran, Christopher A, Liu, Chang, Bruno, Tullia C, Workman, Creg J, Vignali, Dario AA · 2020 · Journal for ImmunoTherapy of Cancer
29. Carcinogenesis and therapeutics: the microbiota perspective
    Tsilimigras, Matthew C. B., Fodor, Anthony, Jobin, Christian · 2017 · Nature Microbiology
30. T Cell Ig and Mucin Domain–Containing Protein 3 Is Recruited to the Immune Synapse, Disrupts Stable Synapse Formation, and Associates with Receptor Phosphatases
    Clayton, Kiera L, Haaland, Matthew S, Douglas-Vail, Matthew B, Mujib, Shariq, Chew, Glen M, Ndhlovu, Lishomwa C, Ostrowski, Mario A · 2014 · The Journal of Immunology
31. Targeting CXCR4-dependent immunosuppressive Ly6C ^low monocytes improves antiangiogenic therapy in colorectal cancer
    Jung, Keehoon, Heishi, Takahiro, Incio, Joao, Huang, Yuhui, Beech, Elizabeth Y., Pinter, Matthias, Ho, William W., Kawaguchi, Kosuke, Rahbari, Nuh N., Chung, Euiheon et al. · 2017 · Proceedings of the National Academy of Sciences
32. PI3K inhibition reduces mammary tumor growth and facilitates antitumor immunity and anti-PD1 responses
    Sai, Jiqing, Owens, Philip, Novitskiy, Sergey V., Hawkins, Oriana E., Vilgelm, Anna E., Yang, Jinming, Sobolik, Tammy, Lavender, Nicole, Johnson, Andrew C., McClain, Colt et al. · 2017 · Clinical Cancer Research
33. Creatine uptake regulates CD8 T cell antitumor immunity
    Di Biase, Stefano, Ma, Xiaoya, Wang, Xi, Yu, Jiaji, Wang, Yu-Chen, Smith, Drake J., Zhou, Yang, Li, Zhe, Kim, Yu Jeong, Clarke, Nicole et al. · 2019 · Journal of Experimental Medicine
34. DKK2 imparts tumor immunity evasion through β-catenin-independent suppression of cytotoxic immune cell activation
    Xiao, Qian, Wu, Jibo, Wang, Wei-Jia, Chen, Shiyang, Zheng, Yingxia, Yu, Xiaoqing, Meeth, Katrina, Sahraei, Mahnaz, Bothwell, Alfred L M, Chen, Lieping et al. · 2018 · Nature Medicine
35. Targeting T cell metabolism in the tumor microenvironment: an anti‐cancer therapeutic strategy
    Yin, Zhongping, Bai, Ling, Li, Wei, Zeng, Tanlun, Tian, Huimin, Cui, Jiuwei · 2019 · Journal of Experimental & Clinical Cancer Research
36. Metabolic communication in tumors: a new layer of immunoregulation for immune evasion
    Ho, Ping-Chih, Liu, Pu-Ste · 2016 · Journal for ImmunoTherapy of Cancer
37. Interferons and the immunogenic effects of cancer therapy
    Minn, Andy J. · 2015 · Trends in Immunology
38. Type I interferons and dendritic cells in cancer immunotherapy
    2019 · International Review of Cell and Molecular Biology
39. Molecular Mechanisms Directing Migration and Retention of Natural Killer Cells in Human Tissues
    Castriconi, Roberta, Carrega, Paolo, Dondero, Alessandra, Bellora, Francesca, Casu, Beatrice, Regis, Stefano, Ferlazzo, Guido, Bottino, Cristina · 2018 · Frontiers in Immunology
40. Subgroup-specific immune and stromal microenvironment in medulloblastoma
    Bockmayr, Michael, Mohme, Malte, Klauschen, Frederick, Winkler, Beate, Budczies, Jan, Rutkowski, Stefan, Schüller, Ulrich · 2018 · OncoImmunology
41. Translational Pharmacokinetic/Pharmacodynamic Modeling of Tumor Growth Inhibition Supports Dose-Range Selection of the Anti-PD-1 Antibody Pembrolizumab
    Lindauer, A, Valiathan, CR, Mehta, K, Sriram, V, de Greef, R, Elassaiss-Schaap, J, de Alwis, DP · 2017 · CPT: Pharmacometrics & Systems Pharmacology
42. Double-edged roles of protein tyrosine phosphatase SHP2 in cancer and its inhibitors in clinical trials
    Song, Yihui, Zhao, Min, Zhang, Huiqing, Yu, Bin · 2022 · Pharmacology & Therapeutics
43. Regorafenib enhances anti-PD1 immunotherapy efficacy in murine colorectal cancers and their combination prevents tumor regrowth
    Doleschel, Dennis, Hoff, Sabine, Koletnik, Susanne, Rix, Anne, Zopf, Dieter, Kiessling, Fabian, Lederle, Wiltrud · 2021 · Journal of Experimental & Clinical Cancer Research
44. Frequent Loss of IRF2 in Cancers Leads to Immune Evasion through Decreased MHC Class I Antigen Presentation and Increased PD-L1 Expression
    Kriegsman, Barry A, Vangala, Pranitha, Chen, Benjamin J, Meraner, Paul, Brass, Abraham L, Garber, Manuel, Rock, Kenneth L · 2019 · The Journal of Immunology
45. CXCL11-Armed oncolytic poxvirus elicits potent antitumor immunity and shows enhanced therapeutic efficacy
    Liu, Zuqiang, Ravindranathan, Roshni, Li, Jun, Kalinski, Pawel, Guo, Z. Sheng, Bartlett, David L. · 2016 · OncoImmunology
46. Emerging Roles for Eosinophils in the Tumor Microenvironment
    Reichman, Hadar, Karo-Atar, Danielle, Munitz, Ariel · 2016 · Trends in Cancer
47. Mismatch repair deficiency is a rare but putative therapeutically relevant finding in non-liver fluke associated cholangiocarcinoma
    Goeppert, Benjamin, Roessler, Stephanie, Renner, Marcus, Singer, Stephan, Mehrabi, Arianeb, Vogel, Monika Nadja, Pathil, Anita, Czink, Elena, Köhler, Bruno, Springfeld, Christoph et al. · 2019 · British Journal of Cancer
48. Phenotype and Function of T Cells Infiltrating Visceral Metastases from Gastrointestinal Cancers and Melanoma: Implications for Adoptive Cell Transfer Therapy
    Turcotte, Simon, Gros, Alena, Hogan, Katherine, Tran, Eric, Hinrichs, Christian S, Wunderlich, John R, Dudley, Mark E, Rosenberg, Steven A · 2013 · The Journal of Immunology
49. Gastrointestinal toxicity of immune checkpoint inhibitors: From mechanisms to management
    Samaan, Mark A., Pavlidis, Polychronis, Papa, Sophie, Powell, Nick, Irving, Peter M. · 2018 · Nature Reviews Gastroenterology & Hepatology
50. Tumor vasculature normalization by orally fed erlotinib to modulate the tumor microenvironment for enhanced cancer nanomedicine and immunotherapy
    Chen, Qian, Xu, Ligeng, Chen, Jiawen, Yang, Zhijuan, Liang, Chao, Yang, Yu, Liu, Zhuang · 2017 · Biomaterials
51. The RNA-binding Protein MEX3B Mediates Resistance to Cancer Immunotherapy by Downregulating HLA-A Expression
    Huang, Lu, Malu, Shruti, McKenzie, Jodi A., Andrews, Miles C., Talukder, Amjad H., Tieu, Trang, Karpinets, Tatiana, Haymaker, Cara, Forget, Marie-Andrée, Williams, Leila J. et al. · 2018 · Clinical Cancer Research
52. Targeting the Interplay between Epithelial-to-Mesenchymal-Transition and the Immune System for Effective Immunotherapy
    Soundararajan, Rama, Fradette, Jared, Konen, Jessica, Moulder, Stacy, Zhang, Xiang, Gibbons, Don, Varadarajan, Navin, Wistuba, Ignacio, Tripathy, Debasish, Bernatchez, Chantale et al. · 2019 · Cancers
53. Cellular senescence and tumor promotion: Is aging the key?
    Loaiza, Natalia, Demaria, Marco · 2016 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
54. Clinical impact of probiotics on the efficacy of <scp>anti‐PD</scp>‐1 monotherapy in patients with nonsmall cell lung cancer: A multicenter retrospective survival analysis study with inverse probability of treatment weighting
    Takada, Kazuki, Shimokawa, Mototsugu, Takamori, Shinkichi, Shimamatsu, Shinichiro, Hirai, Fumihiko, Tagawa, Tetsuzo, Okamoto, Tatsuro, Hamatake, Motoharu, Tsuchiya‐Kawano, Yuko, Otsubo, Kohei et al. · 2021 · International Journal of Cancer
55. Comprehensive assessment of multiple tryptophan metabolites as potential biomarkers for immune checkpoint inhibitors in patients with non-small cell lung cancer
    Karayama, M., Masuda, J., Mori, K., Yasui, H., Hozumi, H., Suzuki, Y., Furuhashi, K., Fujisawa, T., Enomoto, N., Nakamura, Y. et al. · 2021 · Clinical and Translational Oncology
56. The role of AhR in transcriptional regulation of immune cell development and function
    Trikha, Prashant, Lee, Dean A. · 2020 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
57. Negative co-stimulation constrains T cell differentiation by imposing boundaries on possible cell states
    Wei, Spencer C., Sharma, Roshan, Anang, Nana-Ama A.S., Levine, Jacob H., Zhao, Yang, Mancuso, James J., Setty, Manu, Sharma, Padmanee, Wang, Jing, Pe’er, Dana et al. · 2019 · Immunity
58. Adoptive T-cell therapy for cancer: the era of engineered T cells
    Bonini, Chiara, Mondino, Anna · 2015 · European Journal of Immunology
59. The importance of immune checkpoints in immune monitoring: A future paradigm shift in the treatment of cancer
    Alemohammad, Hajar, Najafzadeh, Basira, Asadzadeh, Zahra, Baghbanzadeh, Amir, Ghorbaninezhad, Farid, Najafzadeh, Arezoo, Safarpour, Hossein, Bernardini, Renato, Brunetti, Oronzo, Sonnessa, Margherita et al. · 2022 · Biomedicine &amp; Pharmacotherapy
60. Polygenic risk for skin autoimmunity impacts immune checkpoint blockade in bladder cancer
    Khan, Zia, Di Nucci, Flavia, Kwan, Antonia, Hammer, Christian, Mariathasan, Sanjeev, Rouilly, Vincent, Carroll, Jonathan, Fontes, Magnus, Ley Acosta, Sergio, Guardino, Ellie et al. · 2020 · Proceedings of the National Academy of Sciences
61. Harnessing and Enhancing Macrophage Phagocytosis for Cancer Therapy
    Chen, Siqi, Lai, Seigmund W. T., Brown, Christine E., Feng, Mingye · 2021 · Frontiers in Immunology
62. Delivery Strategies for Immune Checkpoint Blockade
    Chen, Qian, Wang, Chao, Chen, Guojun, Hu, Quanyin, Gu, Zhen · 2018 · Advanced Healthcare Materials
63. Immune-mediated drug-induced liver injury: immunogenetics and experimental models
    Gerussi, Alessio, Natalini, Ambra, Antonangeli, Fabrizio, Mancuso, Clara, Agostinetto, Elisa, Barisani, Donatella, Di Rosa, Francesca, Andrade, Raul, Invernizzi, Pietro · 2021 · International Journal of Molecular Sciences
64. Haematological malignancies: at the forefront of immunotherapeutic innovation
    Bachireddy, Pavan, Burkhardt, Ute E., Rajasagi, Mohini, Wu, Catherine J. · 2015 · Nature Reviews Cancer
65. PD-L1 and IAPs co-operate to protect tumors from cytotoxic lymphocyte-derived TNF
    Kearney, Conor J, Lalaoui, Najoua, Freeman, Andrew J, Ramsbottom, Kelly M, Silke, John, Oliaro, Jane · 2017 · Cell Death &amp; Differentiation
66. Tumour-targeted interleukin-12 and entinostat combination therapy improves cancer survival by reprogramming the tumour immune cell landscape
    Hicks, Kristin C., Chariou, Paul L., Ozawa, Yohei, Minnar, Christine M., Knudson, Karin M., Meyer, Thomas J., Bian, Jing, Cam, Margaret, Schlom, Jeffrey, Gameiro, Sofia R. · 2021 · Nature Communications
67. Dual blockage of both PD-L1 and CD47 enhances immunotherapy against circulating tumor cells
    Lian, Shu, Xie, Ruizhi, Ye, Yuying, Lu, Yusheng, Cheng, Yunlong, Xie, Xiaodong, Li, Shuhui, Jia, Lee · 2019 · Scientific Reports
68. <i>Escherichia coli</i> –Specific CXCL13-Producing TFH Are Associated with Clinical Efficacy of Neoadjuvant PD-1 Blockade against Muscle-Invasive Bladder Cancer
    Goubet, Anne-Gaëlle, Lordello, Leonardo, Alves Costa Silva, Carolina, Peguillet, Isabelle, Gazzano, Marianne, Mbogning-Fonkou, Maxime Descartes, Thelemaque, Cassandra, Lebacle, Cédric, Thibault, Constance, Audenet, François et al. · 2022 · Cancer Discovery
69. STAT3 Inhibition Combined with CpG Immunostimulation Activates Antitumor Immunity to Eradicate Genetically Distinct Castration-Resistant Prostate Cancers
    Moreira, Dayson, Adamus, Tomasz, Zhao, Xingli, Su, Yu-Lin, Zhang, Zhuoran, White, Seok Voon, Swiderski, Piotr, Lu, Xin, DePinho, Ronald A., Pal, Sumanta K. et al. · 2018 · Clinical Cancer Research
70. Tasquinimod triggers an early change in the polarization of tumor associated macrophages in the tumor microenvironment
    Olsson, Anders, Nakhlé, Jessica, Sundstedt, Anette, Plas, Pascale, Bauchet, Anne-Laure, Pierron, Valérie, Bruetschy, Luce, Deronic, Adnan, Törngren, Marie, Liberg, David et al. · 2015 · Journal for ImmunoTherapy of Cancer
71. Tumor-infiltrating immune cells as potential biomarkers predicting response to treatment and survival in patients with metastatic melanoma receiving ipilimumab therapy
    Balatoni, Tímea, Mohos, Anita, Papp, Eszter, Sebestyén, Tímea, Liszkay, Gabriella, Oláh, Judit, Varga, Anita, Lengyel, Zsuzsanna, Emri, Gabriella, Gaudi, István et al. · 2018 · Cancer Immunology, Immunotherapy
72. Efficient Delivery of GSDMD‐N mRNA by Engineered Extracellular Vesicles Induces Pyroptosis for Enhanced Immunotherapy
    Xing, Yuqi, Zhang, Feiyu, Ji, Panpan, Wei, Mengying, Yin, Chunhui, Yang, Angang, Yang, Guodong, Zhao, Jing · 2023 · Small
73. Distinct PD-L1/PD1 profiles and clinical implications in intrahepatic cholangiocarcinoma patients with different risk factors
    Lu, Jia-Cheng, Zeng, Hai-Ying, Sun, Qi-Man, Meng, Qing-Nan, Huang, Xiao-Yong, Zhang, Peng-Fei, Yang, Xuan, Peng, Rui, Gao, Chao, Wei, Chuan-Yuan et al. · 2019 · Theranostics
74. Different syngeneic tumors show distinctive intrinsic tumor-immunity and mechanisms of actions (MOA) of anti-PD-1 treatment
    Jin, Ying, An, Xiaoyu, Mao, Binchen, Sun, Ruilin, Kumari, Rajendra, Chen, Xiaobo, Shan, Yongli, Zang, Mingfa, Xu, Ling, Muntel, Jan et al. · 2022 · Scientific Reports
75. Modulation of Gut Microbiota: A Novel Paradigm of Enhancing the Efficacy of Programmed Death-1 and Programmed Death Ligand-1 Blockade Therapy
    Wang, Yiming, Ma, Rena, Liu, Fang, Lee, Seul A., Zhang, Li · 2018 · Frontiers in Immunology
76. Age-associated inflammation connects ras-induced senescence to stem cell dysfunction and epidermal malignancy
    Golomb, L, Sagiv, A, Pateras, I S, Maly, A, Krizhanovsky, V, Gorgoulis, V G, Oren, M, Ben-Yehuda, A · 2015 · Cell Death &amp; Differentiation
77. LAG-3 and PD-1+LAG-3 inhibition promote anti-tumor immune responses in human autologous melanoma/T cell co-cultures
    Gestermann, Nicolas, Saugy, Damien, Martignier, Christophe, Tillé, Laure, Fuertes Marraco, Silvia A., Zettl, Markus, Tirapu, Iñigo, Speiser, Daniel E., Verdeil, Grégory · 2020 · OncoImmunology
78. Dual PD-1 and CTLA-4 checkpoint blockade promotes antitumor immune responses through CD4(+)Foxp3(-) cell-mediated modulation of CD103(+) dendritic cells
    Beavis, Paul A., Henderson, Melissa A., Giuffrida, Lauren, Davenport, Alexander J., Petley, Emma V., House, Imran G., Lai, Junyun, Sek, Kevin, Milenkovski, Nicole, John, Liza B. et al. · 2018 · Cancer Immunology Research
79. The Pathogenesis of Tuberculosis-The Koch Phenomenon Reinstated.
    Hunter, Robert L. · 2020 · Pathogens
80. Antibody-Cytokine Fusion Proteins for Treatment of Cancer: Engineering Cytokines for Improved Efficacy and Safety
    Young, Patricia A., Morrison, Sherie L., Timmerman, John M. · 2014 · Seminars in Oncology
81. Adverse events associated with immune checkpoint inhibitor treatment for cancer
    Esfahani, Khashayar, Meti, Nicholas, Miller, Wilson H., Hudson, Marie · 2019 · Canadian Medical Association Journal
82. Considerations for successful cancer immunotherapy in aged hosts
    Hurez, V, Padrón, Á S, Svatek, R S, Curiel, T J · 2016 · Clinical and Experimental Immunology
83. High-capacity poly (2-oxazoline) formulation of TLR 7/8 agonist extends survival in a chemo-insensitive, metastatic model of lung adenocarcinoma
    Vinod, Natasha, Hwang, Duhyeong, Azam, Salma H., Van Swearingen, Amanda E. D., Wayne, Elizabeth, Fussell, Sloane Christian, Sokolsky-Papkov, Marina, Pecot, Chad V., Kabanov, Alexander V. · 2020 · Science Advances
84. Rational Design of Potent Peptide Inhibitors of the PD-1:PD-L1 Interaction for Cancer Immunotherapy
    Yin, Huawu, Zhou, Xiuman, Huang, Yen-Hua, King, Gordon J., Collins, Brett M., Gao, Yanfeng, Craik, David J., Wang, Conan K. · 2021 · Journal of the American Chemical Society
85. Immunogenicity of pembrolizumab in patients with advanced tumors
    van Vugt, Marianne J. H., Stone, Julie A., De Greef, “Rik” H. J. M. M., Snyder, Ellen S., Lipka, Leslie, Turner, David C., Chain, Anne, Lala, Mallika, Li, Mengyao, Robey, Seth H. et al. · 2019 · Journal for ImmunoTherapy of Cancer
86. Immunogenic sonodynamic therapy for inducing immunogenic cell death and activating antitumor immunity
    Wang, Ting, Peng, Wangrui, Du, Meng, Chen, Zhiyi · 2023 · Frontiers in Oncology
87. Modular Hydrogel Vaccine for Programmable and Coordinate Elicitation of Cancer Immunotherapy
    Ji, Panpan, Sun, Wenqi, Zhang, Siyan, Xing, Yuqi, Wang, Chen, Wei, Mengying, Li, Qiuyun, Ji, Gang, Yang, Guodong · 2023 · Advanced Science
88. Therapeutic Cancer Vaccines—T Cell Responses and Epigenetic Modulation
    Kartikasari, Apriliana E. R., Prakash, Monica D., Cox, Momodou, Wilson, Kirsty, Boer, Jennifer C., Cauchi, Jennifer A., Plebanski, Magdalena · 2019 · Frontiers in Immunology
89. Immune checkpoint inhibitors associated cardiovascular immune-related adverse events
    Jo, Wonyoung, Won, Taejoon, Daoud, Abdel, Čiháková, Daniela · 2024 · Frontiers in Immunology
90. Regulatory T cells and M2 macrophages present diverse prognostic value in gastric cancer patients with different clinicopathologic characteristics and chemotherapy strategies
    Liu, Xu, Xu, Danhua, Huang, Chen, Guo, Yixian, Wang, Shuchang, Zhu, Chunchao, Xu, Jia, Zhang, Zizhen, Shen, Yanying, Zhao, Wenyi et al. · 2019 · Journal of Translational Medicine
91. Immunotherapies targeting stimulatory pathways and beyond
    Marin-Acevedo, Julian A., Kimbrough, ErinMarie O., Manochakian, Rami, Zhao, Yujie, Lou, Yanyan · 2021 · Journal of Hematology &amp; Oncology
92. Innate Inspiration: Antifungal Peptides and Other Immunotherapeutics From the Host Immune Response
    Mercer, Derry K., O'Neil, Deborah A. · 2020 · Frontiers in Immunology
93. Interferons: role in cancer therapy
    Abdolvahab, Mohadeseh Haji, Darvishi, Behrad, Zarei, Mohammad, Majidzadeh-A, Keivan, Farahmand, Leila · 2020 · Immunotherapy
94. Mechanisms of idiosyncratic drug-induced liver injury
    Uetrecht, Jack · 2019 · Advances in pharmacology
95. Decursin promotes HIF-1α proteasomal degradation and immune responses in hypoxic tumour microenvironment
    Ge, Yun, Yoon, Soo-Hyun, Jang, Hyeonha, Jeong, Ji-Hak, Lee, You-Mie · 2020 · Phytomedicine
96. Immunotherapies for pediatric cancer: current landscape and future perspectives
    Hutzen, Brian, Paudel, Siddhi Nath, Naeimi Kararoudi, Meisam, Cassady, Kevin A., Lee, Dean A., Cripe, Timothy P. · 2019 · Cancer and Metastasis Reviews
97. Cooperative immune-mediated mechanisms of the HDAC inhibitor entinostat, an IL15 superagonist, and a cancer vaccine effectively synergize as a novel cancer therapy
    Hicks, Kristin C., Knudson, Karin M., Lee, Karin L., Hamilton, Duane H., Hodge, James W., Figg, William D., Ordentlich, Peter, Jones, Frank R., Rabizadeh, Shahrooz, Soon-Shiong, Patrick et al. · 2020 · Clinical Cancer Research
98. Age effects of distinct immune checkpoint blockade treatments in a mouse melanoma model
    Padrón, Álvaro, Hurez, Vincent, Gupta, Harshita B., Clark, Curtis A., Pandeswara, Sri Lakshmi, Yuan, Bin, Svatek, Robert S., Turk, Mary Jo, Drerup, Justin M., Li, Rong et al. · 2018 · Experimental Gerontology
99. Modulation of dendritic cell and T cell cross-talk during aging: The potential role of checkpoint inhibitory molecules
    Gardner, Joanne K., Mamotte, Cyril D.S., Jackaman, Connie, Nelson, Delia J. · 2017 · Ageing Research Reviews
100. Immunotherapy: Recent Advances and Its Future as a Neoadjuvant, Adjuvant, and Primary Treatment in Colorectal Cancer
     Yu, Irene, Dakwar, Anthony, Takabe, Kazuaki · 2023 · Cells